FDA warned buy-pharma.md that its website sells unapproved prescription drugs, including azithromycin and hydroxychloroquine, with COVID-19 claims.
What happened
FDA reviewed the website www.buy-pharma.md on January 5, 2021. It found the site offered prescription drugs for sale in the U.S., including azithromycin and hydroxychloroquine listed under a “Coronavirus” tab, with statements that they might be effective against Coronavirus but had not been proven. FDA said there were no approved applications for the named products and that the drugs were unapproved and misbranded.
What FDA found
The website sold unapproved new drugs in the U.S. without FDA approval.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The website put azithromycin under a “Coronavirus” tab and said it might be effective against Coronavirus, though it has not been proven and FDA has not approved azithromycin for COVID-19.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The website put hydroxychloroquine under a “Coronavirus” tab and said it might be effective against Coronavirus, though it has not been proven and FDA has not approved hydroxychloroquine for COVID-19.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The prescription drugs’ labeling did not include adequate directions for safe use by a layperson.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]Offering the drugs to U.S. consumers caused misbranded drugs to be introduced into interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop selling the unapproved and misbranded products and to email a description of corrective steps, with supporting documents, within 48 hours. If it cannot finish within 48 hours, it must explain why and give the time it will complete the corrections.
Who should pay attention
- online pharmacies and websites selling prescription drugs
- consumers who buy medicines from foreign websites
- companies monitoring unauthorized online sales of their brands
This is a summary. Read the original letter on fda.gov.